한국갤럽조사연구소

비상장계속사업자

GALLUP KOREA co.,ltd

박무익

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

한국갤럽조사연구소

Business Reg. No. 1028141325 · CEO 박무익

I.Investment Overview

Target한국갤럽조사연구소 (1028141325)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명한국갤럽조사연구소
영문명GALLUP KOREA co.,ltd
대표자박무익
사업자등록번호1028141325
법인등록번호1101110166474
설립일1974.06.17

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW321.22021346.52022425.62023437.32024466.62025
영업이익100M KRW18202123.6202231.1202321.2202424.62025
순이익100M KRW13.7202113.6202229.9202322.8202436.62025
Item20252024202320222021
자산총계326.8억원314.1억원326.4억원298.3억원321억원
부채총계77.1억원93.3억원120.6억원117.4억원143.7억원
자본총계249.7억원220.8억원205.8억원180.9억원177.3억원
매출액466.6억원437.3억원425.6억원346.5억원321.2억원
영업이익24.6억원21.2억원31.1억원23.6억원18억원
순이익36.6억원22.8억원29.9억원13.6억원13.7억원

VI.Financial Ratios

FY2025 basis

5.26%

영업이익률

7.84%

순이익률

11.19%

ROA

14.65%

ROE

30.88%

부채비율

76.41%

자기자본비율

VII.R&D Activity

Fields 보건의료 > 한의과학 · 보건의료 > 의약품안전관리 · 농림수산식품 > 식품과학

Keywords 생약, 식중독균, 검출법, 식품 안전, 약용식물

YearProjectsPapersPatents
2024300
2023100
2022100
2021300
2020300
2019300
2018200
2017200
2015110
2012300
2010100

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

한국갤럽조사연구소 투심보고서 | Alpha Lenz